Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Loading...
Community
/
Switzerland
/
Pharmaceuticals & Biotech
/
Tecan Group
Create a narrative
Tecan Group Community
SWX:TECN Community
3
Narratives
written by author
0
Comments
on narratives written by author
6
Fair Values set
on narratives written by author
Community Investing Ideas
Tecan Group
Popular
Undervalued
Overvalued
Tecan Group
AN
AnalystHighTarget
Consensus Narrative from 9 Analysts
Lab Automation And Personalized Medicine Will Unlock Secular Opportunities
Key Takeaways Structural cost and manufacturing advantages, combined with strong recurring revenues, position Tecan for expanding margins and resilience against macro and regulatory shocks. Accelerated innovation, increasing commercial adoption, and strategic partnerships drive faster market share gains, enabling robust, sustainable revenue and profit growth.
View narrative
CHF 351.3
FV
55.2% undervalued
intrinsic discount
16.10%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
7 days ago
author updated this narrative
Tecan Group
AN
AnalystConsensusTarget
Consensus Narrative from 9 Analysts
Advanced Automation And Personalized Medicine Will Shape Healthcare's Future
Key Takeaways Rising demand in diagnostics and successful automation launches position Tecan for growth and increased profitability through digital healthcare transformation. Expanding recurring revenues, operational efficiencies, and a sizable share buyback support stable earnings and management's confidence in long-term prospects.
View narrative
CHF 220.47
FV
28.6% undervalued
intrinsic discount
6.68%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
13 days ago
author updated this narrative
Tecan Group
AN
AnalystLowTarget
Consensus Narrative from 9 Analysts
Tariffs And Disruptions Will Crush Margins While Cuts Will Help
Key Takeaways Heightened regulatory, compliance, and macroeconomic risks are pressuring margins and clouding growth prospects, with irregular demand and weak visibility on future revenues. Technological shifts and industry digitalization threaten Tecan's competitive edge, while customer concentration and supply chain disruptions further increase earnings instability.
View narrative
CHF 165.2
FV
4.7% undervalued
intrinsic discount
3.79%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 1 month ago
author updated this narrative